ABBVIE INC. (NYSE:ABBV) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

ABBVIE INC. (NYSE:ABBV) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.Submission of Matters to a Vote of Security Holders.

AbbVie Inc. (“AbbVie”) held its Annual Meeting of Stockholders on May4, 2018. The following is a summary of the matters voted on at that meeting.

(1) The stockholders elected AbbVie’s ClassIII Directors with terms expiring in 2021, as follows:

Name

For

Against

BrokerNon-Votes

Roxanne S. Austin

1,136,868,599

13,161,295

260,703,800

Richard A. Gonzalez

1,115,140,717

34,889,177

260,703,800

Rebecca B. Roberts

1,139,178,279

10,851,615

260,703,800

Glenn F. Tilton

1,129,746,144

20,283,750

260,703,800

(2) The stockholders ratified the appointment of Ernst& Young LLP as AbbVie’s independent registered public accounting firm for 2018, as follows:

For

Against

Abstain

1,397,789,476

9,779,337

3,164,881

(3) The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement for the 2018 annual meeting, as follows:

For

Against

Abstain

BrokerNon-Votes

1,091,537,665

52,278,080

6,214,149

260,703,800

(4) The stockholders approved, on an advisory basis, the frequency of the vote to approve the compensation of AbbVie’s named executive officers, as follows:

1Year

2Years

3Years

Abstain

BrokerNon-Votes

1,119,508,603

5,474,102

19,509,034

5,538,155

260,703,800

(5) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation for the annual election of directors, as follows:

For

Against

Abstain

BrokerNon-Votes

1,142,267,330

4,446,678

3,315,886

260,703,800

(6) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows:

For

Against

Abstain

BrokerNon-Votes

1,139,337,651

7,165,827

3,526,416

260,703,800

(7) The stockholders did not approve a stockholder proposal to issue a lobbying report, as follows:

For

Against

Abstain

BrokerNon-Votes

272,992,743

848,877,882

28,159,269

260,703,800

(8) The stockholders did not approve a stockholder proposal to separate chair and CEO, as follows:

For

Against

Abstain

BrokerNon-Votes

441,926,892

702,905,620

5,197,382

260,703,800

(9) The stockholders did not approve a stockholder proposal to issue an annual Compensation Committee report on drug pricing, as follows:

For

Against

Abstain

BrokerNon-Votes

247,879,964

887,590,325

14,559,605

260,703,800


About ABBVIE INC. (NYSE:ABBV)

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.